Neue Studien: Europe PMChttps://www.psoriasis-news.de/articles.html/1_articles/page/9/?d=1Neue Studien: Europe PMCdeThe Psoriatic Disease Assessment Index (PSODAI) Score to Evaluate Systemic Involvement of Psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/the-psoriatic-disease-assessment-index-psodai-score-to-evaluate-systemic-involvement-of-psoriasis-r483/BackgroundTo the best of our knowledge, no validated scoring instrument currently exists that comprehensively evaluates both cutaneous manifestations and systemic comorbidities of psoriasis. This multicenter study aimed to develop and validate a novel multidimensional scoring system addressing this clinical gap.

Methods

Under the guidance of the Shenzhen Psoriasis Academy, we conducted seven expert meetings to analyze existing evidence from PubMed, Wanfang, and CNKI databases. Through iterative Delphi consensus processes involving 26 specialists across 10 disciplines, we established the Psoriasis Disease Assessment Index (PSODAI). This 60-point composite instrument evaluates cutaneous involvement and nine key organ/system comorbidities. An accompanying online calculator (http://www.psodai.com.cn/) was developed for clinical implementation. Validation involved 254 psoriasis patients from six tertiary centers, with comparative analyses against PASI and DLQI metrics.

Results

The PSODAI framework stratifies disease severity as mild (0-20), moderate (21-40), and severe (41-60). Comparative analysis revealed comparable proportions of moderate-to-severe cases between PSODAI and conventional tools (PASI/DLQI) (p>0.05). Notably, 11 patients (4.3%) classified as severe by PASI were re-categorized as mild through PSODAI's systemic evaluation, primarily due to limited extracutaneous manifestations.

Conclusion

As the first comorbidity-integrated assessment tool, PSODAI enables cross-specialty collaboration for holistic patient management. Its clinical adoption may facilitate timely comorbidity detection and preventive interventions. Further multicenter validation is warranted to confirm these preliminary findings.

Weiterlesen

]]>483Thu, 26 Feb 2026 07:51:29 +0000On-label persistence in psoriasis after switching to guselkumab, tumor necrosis factor inhibitors, interleukin-17 inhibitors, or apremilast from other advanced therapies.https://www.psoriasis-news.de/articles.html/1_articles/on-label-persistence-in-psoriasis-after-switching-to-guselkumab-tumor-necrosis-factor-inhibitors-interleukin-17-inhibitors-or-apremilast-from-other-advanced-therapies-r482/ObjectiveTo compare on-label persistence among adults with psoriasis who switched from other advanced therapies to guselkumab versus subcutaneous tumor necrosis factor inhibitors (SC TNFi), subcutaneous interleukin-17 inhibitors (SC IL-17i), or apremilast.

Materials and methods

This retrospective cohort study used U.S. claims data from the IQVIA PharMetrics® Plus database (2016- 2023). Overlap propensity score weights were used to balance cohorts on baseline characteristics. On-label persistence was defined as the absence of drug discontinuation (event) and any dose change relative to the U.S. label (censoring). Survival analyses were used to assess on-label persistence from the start of the maintenance phase.

Results

At 12, 18, and 24 months after the start of the maintenance phase, respectively, on-label persistence was 190%, 180%, and 179% more likely on guselkumab versus SC TNFi; 78%, 87%, and 91% more likely on guselkumab versus SC IL-17i; and 187%, 199%, and 193% more likely on guselkumab versus apremilast (all p < 0.001).

Conclusions

Patients experiencing suboptimal outcomes with other psoriasis-indicated advanced therapies achieved higher on-label persistence after switching to guselkumab, raising the potential for improved disease control relative to other treatment options.

Weiterlesen

]]>482Thu, 26 Feb 2026 07:51:29 +0000Activation of NF-κB signaling in tissue-resident memory T cells promotes recurrent psoriasis in micehttps://www.psoriasis-news.de/articles.html/1_articles/activation-of-nf-%CE%BAb-signaling-in-tissue-resident-memory-t-cells-promotes-recurrent-psoriasis-in-mice-r481/No abstract supplied.

Weiterlesen

]]>481Thu, 26 Feb 2026 07:51:29 +0000Toward the definition of moderate psoriasis: an expert opinion.https://www.psoriasis-news.de/articles.html/1_articles/toward-the-definition-of-moderate-psoriasis-an-expert-opinion-r480/BackgroundThe clinical definition of moderate psoriasis is debated, affecting treatment eligibility and patient outcomes.

Objective

A panel of Italian dermatologists aimed to propose practical criteria to define moderate psoriasis, based on a comprehensive literature review and clinical experience.

Methods

The panel reviewed publications between 2016 and 2024 focusing on key severity scores, including the Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), Dermatology Life Quality Index (DLQI), and Physician's Global Assessment (PGA), along with special area involvement and patient-reported outcomes.

Results

Despite variability among studies, and the lack of universally accepted thresholds, the panel defined moderate psoriasis as a BSA of 5%-10%, DLQI of 5-10, a PGA score of 3, and involvement of at least two special areas (e.g. scalp, face, genitals, nails, hands, or feet). Distressing itch and psychosocial impact were also recognized as critical elements influencing perceived disease burden. A composite PGA-based approach, integrating objective measures with patient-centered criteria, is proposed for identifying patients with moderate psoriasis who may benefit from systemic therapy.

Conclusion

This pragmatic approach may help bridge the gap between guidelines and real-world clinical practice, ensuring more accurate treatment allocation and reducing undertreatment of psoriasis.

Weiterlesen

]]>480Thu, 26 Feb 2026 07:51:29 +0000Perceptions over biologics for psoriasis after 5 years of access in Brazil: a cross-sectional study.https://www.psoriasis-news.de/articles.html/1_articles/perceptions-over-biologics-for-psoriasis-after-5-years-of-access-in-brazil-a-cross-sectional-study-r479/BackgroundBiologic therapies have transformed psoriasis management, and their incorporation into Brazil's public healthcare system (SUS) in 2019 expanded access nationwide. However, real-world utilization and perceptions remain incompletely understood.

Objectives

To evaluate perceptions, barriers, and prescription patterns regarding biologic therapy among Brazilian dermatologists and patients five years after universal incorporation, while quantifying the prevalence of undertreatment.

Methods

We conducted two independent cross-sectional online surveys throughout 2024 among dermatologists (n = 225) and patients with psoriasis or psoriatic arthritis (n = 1,001). Data on demographics, clinical characteristics, and perceived barriers were analyzed.

Results

Overall, 64.9% of dermatologists prescribed biologics, with higher prescribing rates among younger physicians (p = 0.022), those with fewer years of practice (p = 0.013), higher patient volumes (p < 0.001), and practice in tertiary centers (p = 0.001). Only 25.5% of patients were receiving biologics, strongly associated with psoriatic arthritis (p < 0.001), with no difference between public and private care. Key barriers included perceptions that conventional therapies are sufficient (59.5%), insufficient training (38.0%), and administrative burden (45.5%), while patients mainly reported safety (45.7%) and cost (30.9%) concerns. Undertreatment was prevalent, affecting over 50% of patients with moderate-to-severe disease. While 71.3% of non-users were willing to start biologics, only 28.0% had received a medical recommendation.

Conclusions

Persistent educational and structural barriers continue to limit optimal biologic use despite formal availability, highlighting the need for targeted education, streamlined care pathways, and improved physician-patient communication to achieve equitable outcomes.

Weiterlesen

]]>479Thu, 26 Feb 2026 07:51:29 +0000Cardiovascular Risk in Psoriasis Compared With Atopic Dermatitis: The Shizuoka Kokuho Database.https://www.psoriasis-news.de/articles.html/1_articles/cardiovascular-risk-in-psoriasis-compared-with-atopic-dermatitis-the-shizuoka-kokuho-database-r478/Weiterlesen

]]>478Thu, 26 Feb 2026 07:51:29 +0000The Association Between the Aggregate Index of Systemic Inflammation (AISI) and Prevalence of Psoriasis: Cross Sectional NHANES Study 2003-2006 and 2009-2014.https://www.psoriasis-news.de/articles.html/1_articles/the-association-between-the-aggregate-index-of-systemic-inflammation-aisi-and-prevalence-of-psoriasis-cross-sectional-nhanes-study-2003-2006-and-2009-2014-r477/Weiterlesen

]]>477Thu, 26 Feb 2026 07:51:29 +0000Coexistence of MOG-IgG-associated bilateral optic neuritis with psoriasis vulgaris and psoriatic arthritis in an Asian patient: a rare case report.https://www.psoriasis-news.de/articles.html/1_articles/coexistence-of-mog-igg-associated-bilateral-optic-neuritis-with-psoriasis-vulgaris-and-psoriatic-arthritis-in-an-asian-patient-a-rare-case-report-r476/No abstract supplied.

Weiterlesen

]]>476Mon, 23 Feb 2026 12:03:16 +0000Targeting the IL-36 Pathway: Spesolimab as a Therapeutic for Acute Flares of Pustular Psoriasishttps://www.psoriasis-news.de/articles.html/1_articles/targeting-the-il-36-pathway-spesolimab-as-a-therapeutic-for-acute-flares-of-pustular-psoriasis-r475/No abstract supplied.

Weiterlesen

]]>475Mon, 23 Feb 2026 12:03:16 +0000Effectiveness and Safety of Roflumilast in the Treatment of Psoriasis: A Systematic Review and Meta-Analysis...https://www.psoriasis-news.de/articles.html/1_articles/effectiveness-and-safety-of-roflumilast-in-the-treatment-of-psoriasis-a-systematic-review-and-meta-analysis-r474/BackgroundPsoriasis, a chronic autoimmune condition, can severely impact patients' well-being. It is characterized by erythema, thickening, and scaling of the skin. Plaque psoriasis, the most prevalent type, affects 80%-90% of psoriasis patients, ranging from localized to severe cases. Although corticosteroids are commonly used to treat psoriasis, prolonged use poses risks. Therefore, alternative therapies are needed. Roflumilast, a potent phosphodiesterase 4 inhibitor, is currently being considered as a treatment for plaque psoriasis.

Methods

We searched four electronic databases (Cochrane Central Register of Controlled Trials, PubMed, Scopus, and Web of Science) up to March 2024 for relevant articles evaluating the efficacy and tolerability of roflumilast in the management of psoriasis. The quality of evidence from trials was assessed using the Cochrane Risk of Bias tool (RoB1). Data from the included studies were extracted into a standardized online sheet and analyzed using RevMan 5.4.

Results

Roflumilast significantly increased the proportion of patients achieving an Investigator's Global Assessment score of 0 or 1 and a 2-point improvement score at both weeks 4 and 8 compared to placebo (RR = 3.48, 95% CI [2.04 to 5.92], P < 0.00001, and RR = 4.02, 95% CI [3.17 to 5.11], P < 0.00001, respectively). The pooled studies demonstrated homogeneity at both weeks 4 (P = 0.17, I² = 38%) and 8 (P = 0.38, I² = 5%). Regarding the results of the Psoriasis Area and Severity Index, 75% favored roflumilast over placebo (RR = 2.72, 95% CI [1.18 to 6.28], P < 0.00001, and RR = 3.41, 95% CI [2.19 to 5.32], P < 0.00001, at weeks 4 and 8, respectively). Subgroup analysis addressed the observed heterogeneity in the results.

Conclusion

This meta-analysis represents the first investigation into the efficacy and safety of roflumilast for treating psoriasis. Results suggest that roflumilast is both effective and well-tolerated in managing psoriasis. However, additional robust clinical trials are needed to validate these observations..

Weiterlesen

]]>474Sun, 22 Feb 2026 17:52:44 +0000Integrating multi-source data and machine learning to Decipher the psoriasis-COPD comorbidity.https://www.psoriasis-news.de/articles.html/1_articles/integrating-multi-source-data-and-machine-learning-to-decipher-the-psoriasis-copd-comorbidity-r473/No abstract supplied.

Weiterlesen

]]>473Sun, 22 Feb 2026 17:52:44 +0000Depressive symptoms and psoriasis: Domain-specific associations in national cohorts.https://www.psoriasis-news.de/articles.html/1_articles/depressive-symptoms-and-psoriasis-domain-specific-associations-in-national-cohorts-r472/BackgroundPsoriasis is frequently accompanied by depression. However, the role of specific symptom domains, including cognitive-affective and somatic symptoms, as well as potential metabolic mediators between psoriasis and depression, remains unclear.

Methods

We analyzed data from the National Health and Nutrition Examination Survey (NHANES, n = 14,964) and the Health and Retirement Study (HRS, n = 4364). Depressive symptoms were classified into cognitive-affective and somatic domains. Cross-sectional associations were evaluated in NHANES, and longitudinal symptom trajectories were identified in HRS using group-based trajectory modeling. Based on genome-wide association study summary statistics, bidirectional and two-step Mendelian randomization (MR) were performed to assess causality and identify plasma metabolite mediators.

Results

In NHANES, total depressive symptoms (OR = 1.03, 95% CI: 1.01-1.06, P = 0.018) and somatic symptoms (OR = 1.08, 95% CI: 1.03-1.12, P = 0.003) showed positive associations with psoriasis, but not cognitive-affective symptoms. In HRS, persistently high trajectories of total (OR = 1.58, 95% CI: 1.08-2.32, P = 0.018) was associated with psoriasis, with no significant association for the cognitive-affective and somatic domains after full adjustment. MR supported a causal relationship of psoriasis on depression and identified sphingomyelin (d17:2/16:0, d18:2/15:0) and urate as mediators, accounting for 10.2% and 6.8% of the total effect, respectively.

Conclusion

Depressive symptoms were linked to psoriasis in both cross-sectional and longitudinal analyses. Lipid and antioxidant-related pathways involving sphingomyelin and urate may mediate the relationship between psoriasis and depression, offering potential targets for intervention.

Weiterlesen

]]>472Sun, 22 Feb 2026 17:52:44 +0000IL-23 Inhibitors in Psoriasis: What Have We Learnt so Far?https://www.psoriasis-news.de/articles.html/1_articles/il-23-inhibitors-in-psoriasis-what-have-we-learnt-so-far-r471/Weiterlesen

]]>471Sun, 22 Feb 2026 17:52:44 +0000Pharmacokinetic-pharmacodynamic modelling of risankizumab using chronic plaque psoriasis real-world data.https://www.psoriasis-news.de/articles.html/1_articles/pharmacokinetic-pharmacodynamic-modelling-of-risankizumab-using-chronic-plaque-psoriasis-real-world-data-r470/AimRisankizumab is a high-cost biologic treatment for chronic plaque psoriasis, an immune-mediated inflammatory disease presenting with painful red scaly skin lesions. Inter-individual heterogeneity in treatment response may be better addressed with personalised rather than fixed dosing. We sought to develop a pharmacokinetic/pharmacodynamic (PK/PD) model to characterise the relationship between risankizumab exposure and treatment response.

Methods

A sequential population PK/PD model was developed using real-world data (UK Biomarkers of Systemic Treatment Outcomes in Psoriasis study) comprising serial PK and Psoriasis Area and Severity Index (PASI) measures. Models were built using R (V4.3.1) and nlmixr2 (V2.1.1.9). One and two-compartment PK models were tested. A maximal effect turnover model was used to describe PASI, with drug effect on lesion development rate (Kin).

Results

The dataset (82 serum risankizumab concentrations; 101 PASI observations) comprised 50 patients with psoriasis (median weight 79.3 kg; age 47 years). PK data were described by a one-compartment model with first-order absorption/elimination. Absorption rate (Ka) was fixed from the literature (0.229). Estimated clearance was 0.34 L/day, and volume of distribution 12.9 L. Baseline PASI at model initiation, drug potency (EC50) and lesion recovery rate (Kout) were estimated at 23.4, 0.11 mg/L and 0.05 day-1, respectively.

Conclusions

Pharmacokinetic parameters were similar to risankizumab clinical trials. Kout estimates aligned with other psoriasis turnover models, highlighting the capture of disease dynamics that may be applied across drugs. This model may inform personalised dosing based on individual patient characteristics, drug exposure and response, to optimise treatment outcomes.

Weiterlesen

]]>470Sun, 22 Feb 2026 17:38:20 +0000Psoriasis beyond the skin: systemic inflammation as a bridge to metabolic and hepatic comorbidities.https://www.psoriasis-news.de/articles.html/1_articles/psoriasis-beyond-the-skin-systemic-inflammation-as-a-bridge-to-metabolic-and-hepatic-comorbidities-r469/Weiterlesen

]]>469Sun, 22 Feb 2026 17:38:20 +0000Survey on the management and patient satisfaction levels in individuals with psoriasis and/or psoriatic arthritis.https://www.psoriasis-news.de/articles.html/1_articles/survey-on-the-management-and-patient-satisfaction-levels-in-individuals-with-psoriasis-andor-psoriatic-arthritis-r468/Weiterlesen

]]>468Sun, 22 Feb 2026 17:38:20 +0000Guselkumab: Pediatric First Approval.https://www.psoriasis-news.de/articles.html/1_articles/guselkumab-pediatric-first-approval-r467/®) is a fully human IgG1λ monoclonal antibody developed by Johnson & Johnson to selectively target the p19 subunit of interleukin (IL)-23, a cytokine that plays a key role in various immune-mediated inflammatory diseases. Guselkumab is approved in multiple countries worldwide, including the USA and those of the EU, for the treatment of adults with moderate-to-severe plaque psoriasis, active psoriatic arthritis, and moderately-to-severely active ulcerative colitis and Crohn's disease. In September 2025, guselkumab received its first pediatric approvals in the USA for the treatment of pediatric patients 6 years of age and older and weighing ≥ 40 kg who either have moderate-to-severe plaque psoriasis and are candidates for systemic therapy or phototherapy, or who have active psoriatic arthritis. Subsequently, guselkumab was approved in December 2025 in the EU for the treatment of moderate-to-severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy. Johnson & Johnson is currently undertaking phase III development of guselkumab in pediatric patients with Crohn's disease and ulcerative colitis in various countries. This article summarizes the milestones in the development of guselkumab leading to these first pediatric approvals for plaque psoriasis and psoriatic arthritis.

Weiterlesen

]]>467Sun, 22 Feb 2026 17:38:20 +0000Persistence and Long-Term Disease Control of Interleukin-17 Inhibitors and Interleukin-23 Inhibitors in Patients with Psoriasis: A Nationwide Cohort Study in Japan.https://www.psoriasis-news.de/articles.html/1_articles/persistence-and-long-term-disease-control-of-interleukin-17-inhibitors-and-interleukin-23-inhibitors-in-patients-with-psoriasis-a-nationwide-cohort-study-in-japan-r466/IntroductionInterleukin-17 inhibitors (IL-17i) and interleukin-23 inhibitors (IL-23i) are advanced therapeutic options for moderate-to-severe psoriasis. In real-world settings, biologic persistence is commonly used as a proxy for effectiveness and safety, and a treatment-free status following biologic discontinuation may provide insights into disease remission. This study aimed to assess persistence and treatment-free status for IL-17i versus IL-23i among biologic-naïve patients with psoriasis in Japan.

Patients and methods

This retrospective cohort study analyzed data from the Japanese Medical Data Vision database from 01 January 2015 to 31 December 2022. Patients diagnosed with psoriasis who initiated IL-17i or IL-23i during this study period were included. Persistence of the index biologic and post-discontinuation treatment-free status were assessed using Kaplan-Meier methodology. Propensity score methods with inverse probability of treatment weighting and matching were employed to control potential confounding between treatment cohorts.

Results

There were 1,751 and 1,721 patients included in the IL-17i cohort and IL-23i cohort, respectively. Persistence rates for IL-17i were 55.7% [95% CI 53.2-58.1%] at the first year and 21.5% [95% CI 18.9-24.2%] at the fourth year, versus 77.7% [95% CI 75.4-79.8%] and 47.8% [95% CI 42.2-53.2%], respectively, for IL-23i. The risk of discontinuation of IL-23i was half that of IL-17i (adjusted hazard ratio [aHR]=0.49 [95% CI 0.44-0.54]). After discontinuation, 19.2% [95% CI 16.1-22.4%] and 31.5% [95% CI 27.8-41.2%] of patients in the IL-17i and IL-23i cohorts, respectively, remained treatment-free for at least 1 year. Patients treated with IL-23i had a lower risk for resuming systemic therapy after biologic discontinuation (aHR=0.57 [95% CI 0.49-0.67]).

Conclusion

IL-23i was associated with longer persistence and a longer post-discontinuation treatment-free period than IL-17i in patients with psoriasis. These findings may provide actionable insights for healthcare providers and patients as they develop treatment strategies. Future research integrating comprehensive clinical data is warranted to evaluate different treatment strategies, thereby informing clinical decision-making.

Weiterlesen

]]>466Sun, 22 Feb 2026 17:38:20 +0000Ixekizumab for the treatment of psoriatic arthritis: an Italian multicentric retrospective observational study.https://www.psoriasis-news.de/articles.html/1_articles/ixekizumab-for-the-treatment-of-psoriatic-arthritis-an-italian-multicentric-retrospective-observational-study-r465/No abstract supplied.

Weiterlesen

]]>465Sun, 22 Feb 2026 17:38:20 +0000Development and validation of a prediction model for the risk of relapse in psoriasishttps://www.psoriasis-news.de/articles.html/1_articles/development-and-validation-of-a-prediction-model-for-the-risk-of-relapse-in-psoriasis-r464/Background This study collected and analyzed clinical data from patients with psoriasis, developing and validating a risk prediction model for psoriasis relapse. The aim is to improve the efficiency and accuracy of early screening for psoriasis relapse in clinical practice and to provide a reference for implementing preventive measures. Objective To develop and validate a risk prediction model for psoriasis relapse. Methods A convenience sampling method was used to select 504 psoriasis patients admitted to a tertiary hospital in China between January 2022 and December 2024, including 353 cases in the training set and 151 cases in the test set. Independent risk factors for psoriasis relapse were identified through univariate analysis and logistic regression analysis to develop a prediction model. A nomogram and SHAP summary plot were generated for model visualization, and the model’s goodness of fit and discriminative ability were evaluated. Results The one-year relapse rate of psoriasis patients after treatment was 66.67%. Logistic regression analysis identified body mass index (BMI), diabetes, biologic agent use, smoking, upper respiratory tract infection (URTI), and non-standard medication as independent risk factors for psoriasis relapse, which were included in the model. The area under the ROC curve (AUC) values for the training and testing sets were 0.767 [95% CI: 0.715–0.818] and 0.704 [95% CI: 0.620–0.789], respectively. The model demonstrated good discrimination and calibration, and decision curve analysis (DCA) showed significant net benefit in both the training and testing sets. Conclusion The psoriasis relapse risk prediction model developed in this study demonstrated good predictive performance. This model can serve as an effective reference for assessing the risk of psoriasis relapse and provides valuable insights for developing personalized prevention strategies for patients.

Weiterlesen

]]>464Sun, 22 Feb 2026 17:38:20 +0000Nanocarriers for Psoriasis Treatment: Insights from a Clinical Trial Registered on the Global Clinical Trials Registry Platform.https://www.psoriasis-news.de/articles.html/1_articles/nanocarriers-for-psoriasis-treatment-insights-from-a-clinical-trial-registered-on-the-global-clinical-trials-registry-platform-r463/Weiterlesen

]]>463Sun, 22 Feb 2026 17:38:20 +0000Observation on The Formation of Neutrophil Extracellular Traps in Psoriatic Peripheral Bloodhttps://www.psoriasis-news.de/articles.html/1_articles/observation-on-the-formation-of-neutrophil-extracellular-traps-in-psoriatic-peripheral-blood-r462/Objective To explore the clinical application value of Neutrophil extracellular traps (NETs) in evaluating psoriasis. Methods 2ml peripheral blood of 63 patients with psoriasis and 27 healthy controls were collected. Neutrophils were isolated by density gradient method, and the formation of NETs was observed by immunofluorescence staining. We then calculated the proportion and fluorescence intensity of NETs and analyzed their correlation with clinical classification, severity, and serological indicators. Furthermore, the skin lesions of 5 patients with psoriasis were collected, and the NETs were observed by immunofluorescence method. Results The proportion and fluorescence intensity of spontaneous NETs in patients with psoriasis were significantly higher than those in healthy controls and were positively correlated with the PASI scores. The generation of NETs in psoriasis patients with metabolic syndrome (MetS) or high-TNF-α was higher than in psoriasis patients without metabolic abnormalities or normal-TNF-α. NETs were also observed in most psoriatic skin specimens. Conclusions The levels of NETs are correlated with the disease severity of psoriasis and patients with metabolic abnormalities and may be used as a clinical indicator to reflect the inflammatory state of psoriasis and metabolic comorbidity of psoriasis for disease evaluation.

Weiterlesen

]]>462Sun, 22 Feb 2026 17:38:20 +0000Psychological Well-Being of Patients with Moderate-to-Severe Plaque Psoriasis Treated with Tildrakizumab: 28-Week Interim Results from a Multicenter Observational Study in Italy Using the DASS-21 Questionnaire, the BLUE Study.https://www.psoriasis-news.de/articles.html/1_articles/psychological-well-being-of-patients-with-moderate-to-severe-plaque-psoriasis-treated-with-tildrakizumab-28-week-interim-results-from-a-multicenter-observational-study-in-italy-using-the-dass-21-questionnaire-the-blue-study-r461/IntroductionPsoriasis is a chronic inflammatory skin disease associated with significant physical and psychological burden. Tildrakizumab, an interleukin-23 p19 inhibitor, has demonstrated efficacy in treating moderate-to-severe plaque psoriasis both in clinical trials and real-world setting. However, limited data are available on the impact of the effective treatment of psoriasis on the psychological health of patients. The aim of this study was to assess changes in psychological well-being, as well as clinical and quality-of-life outcomes, in patients with moderate-to-severe plaque psoriasis treated with tildrakizumab in routine clinical practice in Italy.

Methods

This was an interim analysis (IA) of a 52-week multicenter, prospective, observational study. Adults with moderate-to-severe plaque psoriasis initiating tildrakizumab were enrolled. Endpoints focused on well-being and psychological health and included changes, from baseline to week 28, in Depression, Anxiety, and Stress Scale-21 (DASS-21) scores, Dermatology Life Quality Index (DLQI), European Social Survey (ESS) items, and World Health Organization-Five Well-Being Index (WHO-5). Effectiveness was also monitored via Psoriasis Area and Severity Index (PASI), and safety via treatment-emergent adverse event reporting.

Results

A total of 115 patients were included (mean age 52.5 years, 60.8% male), 102 receiving ≥ 1 dose of tildrakizumab and completing DASS-21 evaluations at baseline and week 28. At week 28, improvements were observed in DASS-21 subscales [depression (- 2.6, 95% CI - 2.0 to - 1.0), anxiety (- 2.3, 95% CI - 2.0 to - 1.0), and stress (- 3.4, 95% CI - 4.0 to - 2.0)], accompanied by marked PASI reduction (- 13.7, 95% CI - 12.8 to - 10.1). DLQI, ESS, and WHO-5 scores also improved. Adverse events were generally mild or moderate, with no unexpected safety signals.

Conclusion

In this real-world IA, tildrakizumab was observed to improve the psychological well-being of patients, reflected by a reduction in all items of the DASS-21 scale and, in parallel, confirmed its effectiveness in managing physical symptoms of psoriasis, establishing its role in the holistic management of psoriasis.

Weiterlesen

]]>461Sun, 22 Feb 2026 17:38:20 +0000Exploring the risk association between psoriasis and chronic obstructive pulmonary disease, and asthma using the NHIS database.https://www.psoriasis-news.de/articles.html/1_articles/exploring-the-risk-association-between-psoriasis-and-chronic-obstructive-pulmonary-disease-and-asthma-using-the-nhis-database-r459/BackgroundAsthma (AS) and chronic obstructive pulmonary disease (COPD) are prevalent chronic airway disorders with shared inflammatory pathways. Considering the systemic inflammatory nature of psoriasis, this study utilized the National Health Interview Survey (NHIS) to investigate its potential association with COPD and AS.

Methods

Data from the 2023 NHIS were analyzed, with participants selected based on specific inclusion criteria. A baseline table was constructed, and multivariate logistic regression models, along with risk stratification analysis, were employed to examine the correlations between psoriasis and COPD and AS. Receiver operating characteristic (ROC) analysis was conducted to assess the predictive value for both conditions.

Results

A total of 27,106 participants were included in the study. Significant differences were observed in the baseline characteristics of psoriasis, age, race, region, gender, education, marital status, employment, income, smoking habits, health status, mental health, disability, heart attack history, BMI, prediabetes, cancer, hypertension, hypercholesterolemia, arthritis, coronary heart disease, stroke, health insurance, anxiety, and depression (P < 0.001). Multivariate logistic regression revealed a strong association between psoriasis and COPD (model 1: OR 2.63, 95% CI: 2.13-3.23, P < 0.001; model 2: OR 2.43, 95% CI: 1.95-2.99, P < 0.001; model 3: OR 1.54, 95% CI: 1.21-1.96, P < 0.001). A similar association was found between psoriasis and AS (model 1: OR 1.68, 95% CI: 1.42-1.97, P < 0.001; model 2: OR 1.74, 95% CI: 1.47-2.05, P < 0.001; model 3: OR 1.32, 95% CI: 1.11-1.56, P < 0.01). The ROC analysis based on model 3 demonstrated substantial predictive power of psoriasis for COPD, with an AUC of 0.881.

Conclusion

Psoriasis was identified to have a strong association with COPD and AS, which provided valuable insights into understanding the pathogenesis of these diseases.

Weiterlesen

]]>459Sun, 22 Feb 2026 17:23:03 +0000Investigating the role of serum human beta defensin-2 in psoriasis and psoriatic arthritis: a case-control study on hBD-2 and CRP, ESR.https://www.psoriasis-news.de/articles.html/1_articles/investigating-the-role-of-serum-human-beta-defensin-2-in-psoriasis-and-psoriatic-arthritis-a-case-control-study-on-hbd-2-and-crp-esr-r458/IntroductionHuman beta-defensin 2 (hBD-2) is an antimicrobial peptide upregulated by IL-17A and TNF-α, important in skin immunity and inflammation. While hBD-2 is elevated in psoriatic skin, its systemic expression and clinical significance remain unclear, particularly in psoriatic arthritis (PsA).

Objectives

To compare serum hBD-2 levels among patients with psoriasis vulgaris, PsA, and healthy controls, and to evaluate its correlation with disease severity and inflammatory markers.

Methods

This case-control study included 66 patients with psoriasis, 30 with PsA, and 67 healthy controls. Serum hBD-2, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) were measured. Psoriasis severity was assessed using the Psoriasis Area and Severity Index (PASI). A p value < 0.05 was considered statistically significant.

Results

Median serum hBD-2 levels were significantly higher in psoriasis and PsA groups compared to controls (p < 0.001), but no significant difference was found between the two patient groups (p: 0.223). In the psoriasis group, hBD-2 showed no significant correlation with PASI (r: 0.218, p: 0.095), CRP (r: 0.158, p: 0.277), or ESR (r: 0.129, p: 0.369). CRP and ESR were significantly higher in the PsA group than in other groups (p < 0.001 and p: 0.002, respectively).

Conclusions

Although serum hBD-2 is elevated in psoriasis and PsA, it does not correlate with clinical or laboratory disease activity in psoriasis. These findings suggest that hBD-2 may reflect local cutaneous immune activation rather than systemic inflammation.

Weiterlesen

]]>458Sun, 22 Feb 2026 17:23:03 +0000